Somatic mutations render human exome and pathogen DNA more similar
暂无分享,去创建一个
[1] Pier Federico Gherardini,et al. High response rate to PD-1 blockade in desmoplastic melanomas , 2017, Nature.
[2] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.
[3] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[4] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[5] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[6] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[7] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[8] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[10] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[11] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[12] A. Levine,et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy , 2017, Nature.
[13] Thomas M. Cover,et al. Elements of Information Theory , 2005 .
[14] R. Bourgon,et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.
[15] Axel Hoos,et al. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies , 2016, Nature Reviews Drug Discovery.
[16] M. Berger,et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy , 2018, Science.
[17] Frank Noé,et al. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation , 2017, Front. Immunol..